Categories: Health

Sanuwave to Participate in the 44th Annual J.P. Morgan Healthcare Conference

EDEN PRAIRIE, Minn., Dec. 10, 2025 (GLOBE NEWSWIRE) — Sanuwave Health, Inc. (the “Company” or “Sanuwave”) (NASDAQ: SNWV), a leading provider of FDA-approved next-generation wound care products, is pleased to announce that it will be attending the upcoming 44th Annual J.P. Morgan Healthcare Conference in San Francisco, CA from January 12th to January 15th 2026.

Those wishing to meet with company management during the conference should reach out to investors@sanuwave.com to schedule a time.

About Sanuwave
Sanuwave Health is focused on the research, development, and commercialization of its patented, non-invasive directed energy medical systems for the repair and regeneration of skin, musculoskeletal tissue, and vascular structures.

Sanuwave’s end-to-end wound care portfolio of regenerative medicine products and product candidates help restore the body’s normal healing processes. Sanuwave applies and researches its patented energy transfer technologies in wound healing, orthopedic/spine, aesthetic/cosmetic, and cardiac/endovascular conditions.

Forward-Looking Statements

This press release may contain “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, such as statements relating to future financial results, production expectations, and plans for future business development activities. Forward-looking statements include all statements that are not statements of historical fact regarding intent, belief or current expectations of the Company, its directors or its officers. Investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, many of which are beyond the Company’s ability to control. Actual results may differ materially from those projected in the forward-looking statements. Among the key risks, assumptions and factors that may affect operating results, performance and financial condition are risks associated with regulatory oversight, the Company’s ability to manage its capital resources, competition and the other factors discussed in detail in the Company’s periodic filings with the Securities and Exchange Commission. The Company undertakes no obligation to update any forward-looking statement, except as may be required by applicable law.

Contact: investors@sanuwave.com 

GlobeNews Wire

Recent Posts

InnoCare Announces First Patient Dosed in the Phase II/III Clinical Trial of Novel TYK2 Inhibitor Soficitinib for Chronic Spontaneous Urticaria in China

BEIJING, Feb. 12, 2026 (GLOBE NEWSWIRE) -- InnoCare Pharma (HKEX: 9969; SSE: 688428), a leading…

1 hour ago

Coherus Oncology, Inc. Announces Pricing of Public Offering of Common Stock

February 12, 2026 21:18 ET  | Source: Coherus Oncology, Inc. REDWOOD CITY, Calif., Feb. 12,…

1 hour ago

Appili Therapeutics Reports Financial and Operational Results for Third Quarter of Fiscal Year 2026

 US$82 Million in Pending Proposals Across Multiple Infectious Disease Programs US$40 Million NIAID Funding Award…

1 hour ago

Hexaware and CareInsight Announce Strategic Partnership to Accelerate AI-driven Healthcare Transformation

MUMBAI, India, Feb. 12, 2026 /PRNewswire/ -- Hexaware Technologies (NSE: HEXT), a global provider of…

1 hour ago

Berlin Heals Successfully Raises Over 10M USD to Expand the New Less Invasive Approach to More Heart Failure Patients

ZUG, Switzerland, Feb. 12, 2026 /PRNewswire/ -- Berlin Heals Holding AG, a MedTech company focused on…

1 hour ago

Enfinity Global Expands Bond Facility to the US with Eiffel Investment Group to $183 Million to Support Growth

MIAMI, Feb. 12, 2026 /PRNewswire/ -- Enfinity Global Inc., a leader in renewable energy, today…

2 hours ago